Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.
GlaxoSmithKline (GSK) announces a significant leadership change as Wendy Becker, a Non-Executive Director and Chair of the Remuneration Committee at GSK, has been appointed as the Chair of the Board of Sony Group Corporation. This appointment reflects Becker’s growing influence and leadership within the corporate sector, potentially enhancing GSK’s strategic connections and influence in the global market.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GSK’s overall stock score is driven by strong financial performance, positive earnings call outcomes, and strategic corporate actions like share buybacks. While technical indicators show weak momentum, the stock’s valuation and promising corporate events enhance its attractiveness.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 10,222,682
Technical Sentiment Signal: Hold
Current Market Cap: £56.79B
Learn more about GSK stock on TipRanks’ Stock Analysis page.